PMID- 21388351
OWN - NLM
STAT- MEDLINE
DCOM- 20110627
LR  - 20111117
IS  - 1399-0039 (Electronic)
IS  - 0001-2815 (Linking)
VI  - 77
IP  - 4
DP  - 2011 Apr
TI  - Vascular endothelial growth factor A and cardiovascular disease in rheumatoid 
      arthritis patients.
PG  - 291-7
LID - 10.1111/j.1399-0039.2010.01625.x [doi]
AB  - To determine the contribution of the vascular endothelial growth factor A (VEGFA) 
      rs2010963 (-634 G>C) and rs1570360 (-1154 G>A) polymorphisms to the risk of 
      cardiovascular (CV) disease in a series of patients with rheumatoid arthritis 
      (RA). Six hundred sixty-one patients fulfilling the 1987 American College of 
      Rheumatology classification criteria for RA, seen at the rheumatology outpatient 
      clinics of the Hospital Xeral-Calde, Lugo, and the Hospital San Carlos, Madrid, 
      Spain, were studied. Patients were genotyped for the VEGFA rs2010963 (-634 G>C) 
      and rs1570360 (-1154 G>A) polymorphisms using predesigned TaqMan single 
      nucleotide polymorphism (SNP) genotyping assay (Applied Biosystems, Foster City, 
      CA). Also, human leukocyte antigen (HLA) DRB1 genotyping was performed using 
      molecular-based methods. Clinical histories of the patients were reviewed for the 
      presence of CV events that were considered to be present if the patient had 
      ischemic heart disease, heart failure, cerebrovascular accident, or peripheral 
      arteriopathy. Also, a subgroup of patients without the history of CV events was 
      assessed for the presence of subclinical atherosclerosis manifested by the 
      presence of endothelial dysfunction by brachial artery reactivity (n = 126) and 
      increased carotid artery intima-media thickness (n = 105) using high resolution 
      Doppler ultrasonography. No significant association between the VEGFA rs2010963 
      and the rs1570360 polymorphisms (neither isolated nor joined as allelic 
      combinations) with clinically evident CV disease was found in this series of 
      patients with RA. It was also the case when we examined the contribution of these 
      polymorphisms to the development of subclinical atherosclerosis. VEGFA 
      polymorphisms do not seem to exert a significant influence on the risk of CV 
      disease in patients with RA.
CI  - (c) 2011 John Wiley & Sons A/S.
FAU - Rodriguez-Rodriguez, L
AU  - Rodriguez-Rodriguez L
AD  - Instituto de Parasitologia y Biomedicina Lopez-Neyra, CSIC, Armilla, Granada, 
      Spain.
FAU - Garcia-Bermudez, M
AU  - Garcia-Bermudez M
FAU - Gonzalez-Juanatey, C
AU  - Gonzalez-Juanatey C
FAU - Vazquez-Rodriguez, T R
AU  - Vazquez-Rodriguez TR
FAU - Miranda-Filloy, J A
AU  - Miranda-Filloy JA
FAU - Fernandez-Gutierrez, B
AU  - Fernandez-Gutierrez B
FAU - Llorca, J
AU  - Llorca J
FAU - Martin, J
AU  - Martin J
FAU - Gonzalez-Gay, M A
AU  - Gonzalez-Gay MA
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Aged
MH  - Alleles
MH  - Arthritis, Rheumatoid/blood/diagnosis/etiology/*genetics
MH  - Cardiovascular Diseases/blood/complications/diagnosis/*genetics
MH  - HLA-DR Antigens/blood/genetics
MH  - HLA-DRB1 Chains
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Polymorphism, Single Nucleotide
MH  - Risk Factors
MH  - Spain
MH  - Vascular Endothelial Growth Factor A/*genetics/metabolism
EDAT- 2011/03/11 06:00
MHDA- 2011/06/28 06:00
CRDT- 2011/03/11 06:00
PHST- 2011/03/11 06:00 [entrez]
PHST- 2011/03/11 06:00 [pubmed]
PHST- 2011/06/28 06:00 [medline]
AID - 10.1111/j.1399-0039.2010.01625.x [doi]
PST - ppublish
SO  - Tissue Antigens. 2011 Apr;77(4):291-7. doi: 10.1111/j.1399-0039.2010.01625.x.